Clicky

Catalent, Inc.(CTLT)

Description: Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment's oral dose forms include softgel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.


Keywords: Biotechnology Biopharmaceutical Life Sciences S&P 500 Pharmacy Pharmacology Health Products Inventory Management Ophthalmic Clinical Services Consumer Health Products Delivery Technologies Logic Products Respiratory Products Somerset Biologic Products Specialty Drugs In The United States Inventory Management Services Oral Products Biologic Product Catalent Scientific Services Softgel

Home Page: www.catalent.com

CTLT Technical Analysis

14 Schoolhouse Road
Somerset, NJ 08873
United States
Phone: 732 537 6200


Officers

Name Title
Mr. John R. Chiminski Exec. Chair of the Board
Mr. Alessandro Maselli CEO & Director
Mr. Thomas P. Castellano Sr. VP & CFO
Mr. Steven L. Fasman Esq. Exec. VP, Corp. Sec. & Chief Admin. Officer
Dr. Aristippos Gennadios Ph.D. Group Pres of Pharma & Consumer Health Segment
Mr. Ricky Hopson Pres & Division Head for Clinical Devel. and Supply
Ms. Karen Murphy Santiago VP & Chief Accounting Office
Mr. Julien Meissonnier VP & Chief Scientific Officer
Mr. Charles Lickfold Sr. VP & Chief Information Officer
Mr. Paul Surdez VP of Investor Relations

Exchange: NYSE

Country: US

Currency: US Dollar ($)

Forward PE: 13.1926
Trailing PE: 20.5705
Price-to-Book MRQ: 1.7713
Price-to-Sales TTM: 1.6504
IPO Date: 2014-07-31
Fiscal Year End: June
Full Time Employees: 19000
Back to stocks